OGEN 5 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ogen 5, and when can generic versions of Ogen 5 launch?
Ogen 5 is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in OGEN 5 is estropipate. There are two drug master file entries for this compound. Additional details are available on the estropipate profile page.
Summary for OGEN 5
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Patent Applications: | 2,766 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OGEN 5 at DailyMed |
US Patents and Regulatory Information for OGEN 5
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | OGEN 5 | estropipate | TABLET;ORAL | 083220-004 | Approved Prior to Jan 1, 1982 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |